▲ +148.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CTI BioPharma in the last 3 months. The average price target is $7.25, with a high forecast of $13.00 and a low forecast of $3.00. The average price target represents a 148.29% upside from the last price of $2.92.
The current consensus among 4 polled investment analysts is to buy stock in CTI BioPharma. This Buy consensus rating has held steady for over two years.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.